These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30771333)

  • 21. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data.
    Dugel PU; Campbell JH; Kiss S; Loewenstein A; Shih V; Xu X; Holekamp NM; Augustin AJ; Ho AC; Gonzalez VH; Whitcup SM
    Retina; 2019 Jan; 39(1):88-97. PubMed ID: 29474302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
    Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Response to Ranibizumab Is Associated with 12-Month Outcome in Diabetic Macular Edema after Prior Macular Laser Therapy.
    Sheu SJ; Lee YY
    Ophthalmologica; 2017; 238(3):139-146. PubMed ID: 28715811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema.
    Moisseiev E; Abbassi S; Thinda S; Yoon J; Yiu G; Morse LS
    Eur J Ophthalmol; 2018 Jan; 28(1):68-73. PubMed ID: 28731494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial.
    Yu HJ; Fuller D; Anand R; Fuller T; Munoz J; Moore C; Kim RS; Schefler AC;
    Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):47-54. PubMed ID: 34463842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
    Pieramici DJ; Wang PW; Ding B; Gune S
    Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
    Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
    Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
    Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F
    Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.
    Elman MJ; Ayala A; Bressler NM; Browning D; Flaxel CJ; Glassman AR; Jampol LM; Stone TW;
    Ophthalmology; 2015 Feb; 122(2):375-81. PubMed ID: 25439614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Elman MJ; Bressler NM; Qin H; Beck RW; Ferris FL; Friedman SM; Glassman AR; Scott IU; Stockdale CR; Sun JK;
    Ophthalmology; 2011 Apr; 118(4):609-14. PubMed ID: 21459214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.